Published Online
on September 24, 2007

A more recent version of this article appeared on November 1, 2007

This Article Full Text (PDF) CME: Take the course for this article: Hypertension: November 2007, Volume 50, Number 5 All Versions of this Article: 50/5/911    most recent HYPERTENSIONAHA.107.095448v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Catena, C. Articles by Sechi, L. A. Search for Related Content PubMed PubMed Citation Articles by Catena, C. Articles by Sechi, L. A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Adrenal Gland Cancer High Blood Pressure Hazardous Substances DB POTASSIUM SPIRONOLACTONE Related Collections Hypertrophy Clinical Studies Other Treatment Related Article

Submitted on May 28, 2007
Revised on June 25, 2007

Long-Term Cardiac Effects of Adrenalectomy or Mineralocorticoid Antagonists in Patients With Primary Aldosteronism

Cristiana Catena; GianLuca Colussi; Roberta Lapenna; Elisa Nadalini; Alessandra Chiuch; Pasquale Gianfagna; and Leonardo A. Sechi^*

From the Division of Internal Medicine, Hypertension and Cardiovascular Unit (C.C., G.C., R.L., E.N., A.C., L.A.S.), and Division of Cardiology (P.G.), Department of Experimental and Clinical Pathology and Medicine, University of Udine, Udine, Italy.

^* To whom correspondence should be addressed. E-mail: sechi{at}uniud.it.

Abstract—Exposure to excess aldosterone results in cardiac damage in hypertensive states. We evaluated the long-term cardiac structural and functional evolution in patients with primary aldosteronism after surgical or medical treatment. Fifty-four patients with primary aldosteronism were enrolled in a prospective study and were followed for a mean of 6.4 years after treatment with adrenalectomy (n=24) or spironolactone (n=30). At baseline, echocardiographic measurements of patients with primary aldosteronism were compared with those of 274 patients with essential hypertension. Patients with primary aldosteronism had greater left ventricular mass, more prevalent left ventricular hypertrophy, lower early:late-wave diastolic filling velocities ratio, and longer deceleration time than patients with essential hypertension but no differences in relative wall thickness and systolic function. During follow-up, average blood pressure was 135/82 and 137/82 mm Hg in patients treated with adrenalectomy and spironolactone, respectively. In the initial 1-year period, left ventricular mass decreased significantly only in adrenalectomized patients. Subsequent changes in left ventricular mass were greater in patients treated with spironolactone, with an overall change from baseline to the end of follow-up that was comparable in the 2 groups. Prevalence of hypertrophy decreased in both treatment groups, whereas diastolic parameters had only mild and nonsignificant improvement. Changes in blood pressure and pretreatment plasma aldosterone were independent predictors of left ventricular mass decrease in both treatment groups. Thus, in the long-term, both adrenalectomy and spironolactone are effective in reducing left ventricular mass in patients with primary aldosteronism, with effects that are partially independent of blood pressure changes.

Key words: adrenalectomy • echocardiography • left ventricular hypertrophy • spironolactone • diastolic filling

Related Article:

Will the Lessons From Primary Aldosteronism Change the Treatment of Hypertension and Left Ventricular Hypertrophy?

Richard J. Auchus and Mark H. Drazner
Hypertension 2007 50: 837-839. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				M. Stowasser Update in Primary Aldosteronism J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 3623 - 3630. [Abstract] [Full Text] [PDF]

				R.-F. Yen, V.-C. Wu, K.-L. Liu, M.-F. Cheng, Y.-W. Wu, S.-C. Chueh, W.-C. Lin, K.-D. Wu, K.-Y. Tzen, C.-C. Lu, et al. 131I-6{beta}-Iodomethyl-19-Norcholesterol SPECT/CT for Primary Aldosteronism Patients with Inconclusive Adrenal Venous Sampling and CT Results J. Nucl. Med., October 1, 2009; 50(10): 1631 - 1637. [Abstract] [Full Text] [PDF]

				N. C. Edwards, R. P. Steeds, P. M. Stewart, C. J. Ferro, and J. N. Townend Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J. Am. Coll. Cardiol., August 4, 2009; 54(6): 505 - 512. [Abstract] [Full Text] [PDF]

				L. A. Sechi, A. Di Fabio, M. Bazzocchi, A. Uzzau, and C. Catena Intrarenal Hemodynamics in Primary Aldosteronism before and after Treatment J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1191 - 1197. [Abstract] [Full Text] [PDF]

				E. Born-Frontsberg, M. Reincke, L. C. Rump, S. Hahner, S. Diederich, R. Lorenz, B. Allolio, J. Seufert, C. Schirpenbach, F. Beuschlein, et al. Cardiovascular and Cerebrovascular Comorbidities of Hypokalemic and Normokalemic Primary Aldosteronism: Results of the German Conn's Registry J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1125 - 1130. [Abstract] [Full Text] [PDF]

				M. L. Muiesan, M. Salvetti, A. Paini, C. Agabiti-Rosei, C. Monteduro, G. Galbassini, E. Belotti, C. Aggiusti, D. Rizzoni, M. Castellano, et al. Inappropriate Left Ventricular Mass in Patients With Primary Aldosteronism Hypertension, September 1, 2008; 52(3): 529 - 534. [Abstract] [Full Text] [PDF]

				B Rayner Primary aldosteronism and aldosterone-associated hypertension J. Clin. Pathol., July 1, 2008; 61(7): 825 - 831. [Abstract] [Full Text] [PDF]

				G. P. Rossi, M. Bolognesi, D. Rizzoni, T. M. Seccia, A. Piva, E. Porteri, G. A.M. Tiberio, S. M. Giulini, E. Agabiti-Rosei, and A. C. Pessina Vascular Remodeling and Duration of Hypertension Predict Outcome of Adrenalectomy in Primary Aldosteronism Patients Hypertension, May 1, 2008; 51(5): 1366 - 1371. [Abstract] [Full Text] [PDF]

				N. M. Kaplan Response to More Fuel to the Debate on the "Epidemic of Primary Aldosteronism" Hypertension, January 1, 2008; 51(1): e3 - e3. [Full Text] [PDF]

				R. J. Auchus and M. H. Drazner Will the Lessons From Primary Aldosteronism Change the Treatment of Hypertension and Left Ventricular Hypertrophy? Hypertension, November 1, 2007; 50(5): 837 - 839. [Full Text] [PDF]